The split in outlook underscores Lilly's strong position in the obesity market, underpinned by more effective drugs and its direct-to-consumer sales strategy.
The prospect of another ally falling in the Middle East will be a worrying one for Moscow, particularly after it has seen other alliances collapse recently.